Date: 2011-12-13
Type of information:
phase: 1
Announcement: initiation
Company: Genentech a member of the Roche Group (USA-Switzerland) - NovImmune (Switzerland)
Product: NI-1401-RG7624
Action mechanism: NI-1401-RG7624 is an anti-IL-17 fully human monoclonal antibody.
Disease:
Therapeutic area:
Country:
Trial details:
Latest
news: Genentech has initiated a First-in-Human study with anti-IL-17 (NI-1401, RG7624), a fully human monoclonal antibody designed to specifically and selectively bind to the human IL-17 family of cytokines. The anti-IL-17 antibody was generated at NovImmune and licensed to Genentech in July 2010. The initiation of the Phase I clinical trial triggers a milestone payment from Genentech of an undisclosed amount.
This product is the fifth NovImmune therapeutic antibody to enter clinical development.
